Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLX-ADC1
- Development stage
- Preclinical
- Lead developer
- VALANX Biotech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
VLX-ADC1 is an antibody-drug conjugate (ADC) being developed by VALANX using its proprietary GoldenSite™ technology platform. The drug is designed to target LIK-1, a specific cell-surface protein, to deliver a cytotoxic payload directly to target-expressing cells. By utilizing the GoldenSite™ platform, VALANX aims to create next-generation protein-drug conjugates with precise site-specific conjugation, potentially improving the therapeutic index and stability of the ADC. It is currently in the early screening and preclinical stage of development.
- Other names
- VLX-ADC1-VALANX-LIK-1-ADC-protein-drug conjugateVLX-ADC-1-VALANX-LIK-1-ADC-protein-drug conjugateVLX-ADC 1-VALANX-LIK-1-ADC-protein-drug conjugate
02
Targets
SLC39A6 (Solute carrier family 39 member 6)
Beyond the preview
Go deeper on VLX-ADC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLX-ADC1.